Right now I think the market is making a statement about the FDA rather than the company. There's not a lot of transparency but the snippets I've seen suggest DOGE is causing mayhem. Despite that challenge, the company's still liable for failure on continuous disclosure, and the latest was they are still on track for Q3 start of the trial.It's all in the FDAs hands though and it seems some investors aren't confident they won't delay further and hence are bailing. I was hoping for a July start, maybe it will be September. Sentiment will do its thing, and it is frustrating for sure, but nothing has changed about the asset itself, the mitral result being the latest example of amazing outcomes. But again, incredibly frustrating. We wait on the FDA gods... The only silver lining is it's cheap buying at the moment
AVR Price at posting:
$5.86 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)